Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin’s lymphoma

References

• American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, Atlanta, GA, USA (2010).
   Google Scholar
• Pfreundschuh M, Trümper L, Österborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol.7(5), 379–391 (2006).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase 3 intergroup trial. Blood108(10), 3295–3301 (2006).
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood104(10), 3064–3071 (2004).
   PubMed Web of Science ®Google Scholar
• Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res.61(13), 5137–5144 (2001).
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99(3), 754–758 (2002).
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood95(12), 3900–3908 (2000).
   PubMed Web of Science ®Google Scholar
• Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br. J. Haematol.144(6), 818–831 (2009).
   PubMed Web of Science ®Google Scholar
• Goldenberg MD. The role of radiolabeled antibodies in the treatment of non-Hodgkin’s lymphoma: the coming of age of radioimmunotherapy. Crit. Rev. Oncol. Hematol.39(1–2), 195–201 (2001).
   PubMed Web of Science ®Google Scholar
• Ahmed S, Winter JN, Gordon LI, Evens AM. Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk. Lymphoma51(7), 1163–1177 (2010).
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res.7(3), 709–723 (2001).
   PubMed Web of Science ®Google Scholar
• Wilson KS, Sehn LH, Berry B et al. CHOP-R therapy overcomes the adverse prognostic influence of Bcl-2 expression in diffuse large B-cell lymphoma. Leuk. Lymphoma48(6), 1102–1109 (2007).
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood101(11), 4279–4284 (2003).
   PubMed Web of Science ®Google Scholar
• Furlan A, Villanova F, Pietrogrande F, Celadin M, Sanzari M, Vianello F. Low-dose fludarabine increases rituximab cytotoxicity in B-cells by triggering caspases activation in vitro. Leuk. Lymphoma51(1), 107–113 (2010).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Laubach J, Mitsiades C et al. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park, NY)24(3 Suppl. 2), 22–29 (2010).
   PubMedGoogle Scholar
• Zhang L, Qian Z, Cai Z et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am. J. Hematol.84(9), 553–559 (2009).
   PubMed Web of Science ®Google Scholar
• Wang M, Han XH, Zhang L et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia22(1), 179–185 (2007).
   PubMedGoogle Scholar
• Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood110(1), 29–36 (2007).
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N. Engl. J. Med.333(23), 1540–1545 (1995).
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br. J. Haematol.143(5), 607–621 (2008).
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J. Clin. Oncol.17(12), 3776–3785 (1999).
   PubMed Web of Science ®Google Scholar
• Sud R, Friedberg JW. Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab. Haematologica93(12), 1776–1780 (2008).
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WLJ, van’t Veer MB et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood111(2), 537–543 (2008).
   PubMed Web of Science ®Google Scholar
• Martin A, Conde E, Arnan M et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica93(12), 1829–1836 (2008).
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J. Clin. Oncol. (Meeting Abstracts)27(15S), 8509–8509 (2009).
   Google Scholar
• Calvo-Villas JM, Martin A, Conde E et al. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. Ann. Oncol.21(9), 1891–1897 (2010).
   PubMedGoogle Scholar
• Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol.28(27), 4184–4190 (2010)
   PubMed Web of Science ®Google Scholar
• Sweetenham JW. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology2005(1), 252–259 (2005).
   Google Scholar
• López A, Gutiérrez A, Palacios A et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a Phase II study. Eur. J. Haematol.80(2), 127–132 (2008).
   PubMed Web of Science ®Google Scholar
• El Gnaoui T, Dupuis J, Belhadj K et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann. Oncol.18(8), 1363–1368 (2007).
   PubMed Web of Science ®Google Scholar
• Vacirca JL, Acs PI, Shimkus BJ, Rosen PJ. Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. (Meeting Abstracts)28(Suppl. 15), 8041–8041 (2010).
   Google Scholar
• Ivanov V, Tabouret E, Chuto G et al. Rituximab – lenalidomide – dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk. Lymphoma51(9), 1–3 (2010).
   Web of Science ®Google Scholar
• Vitolo U, Ferreri AJM, Montoto S. Follicular lymphomas. Crit. Rev. Oncol. Hematol.66(3), 248–261 (2008).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J. Clin. Oncol.27(8), 1202–1208 (2009).
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol.26(28), 4579–4586 (2008).
   PubMed Web of Science ®Google Scholar
• Salles GA, Seymour JF, Feugier P. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J. Clin. Oncol. (Meeting Abstracts)28(Suppl. 15), 8004 (2010).
   Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim S-Z et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol.23(15), 3383–3389 (2005).
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood104(5), 1258–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL et al. Bendamustine, bortezomib and rituximab in patients relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter Phase II clinical trial. Blood (ASH Annual Meeting Abstracts)114(22), 924–924 (2009).
   Google Scholar
• Fowler N, Kahl BS, Rosen P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the Phase 2 VERTICAL study. Blood (ASH Annual Meeting Abstracts)114(22), 933–933 (2009).
   PubMedGoogle Scholar
• Weide R, Hess G, Köppler H et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter Phase II study of the German low grade lymphoma study Group (GLSG). Leuk. Lymphoma48(7), 1299–1306 (2007).
   PubMed Web of Science ®Google Scholar
• DeRook I, Odonnell RT, Noble B, Quirch C, Tuscano J. R2: Preliminary results of a Phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin’s lymphoma (NHL). Blood (ASH Annual Meeting Abstracts)112(11), 3060 (2008).
   Google Scholar
• Dutia M, DeRoock I, Chee K et al. R2: preliminary results of a Phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin’s lymphoma (NHL). Blood (ASH Annual Meeting Abstracts)114(22), 1679–1679 (2009).
   Google Scholar
• Ahmadi T, Chong EA, Gordon A et al. Phase II trial of lenalidomide–dexamethasone–rituximab in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab. Blood (ASH Annual Meeting Abstracts)114(22), 1700 (2009).
   Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst.101(4), 248–255 (2009).
   PubMed Web of Science ®Google Scholar
• Ujjani C, Cheson BD. Monoclonal antibodies in advanced B-cell lymphomas. Oncology (Williston Park, NY)24(2), 156–166 (2010).
   PubMedGoogle Scholar
• Borgerding A, Hasenkamp J, Glass B, Wulf G, Trümper L. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann. Hematol.89(3), 283–289 (2009).
   PubMedGoogle Scholar
• Wang M, Fayad L, Cabanillas F et al. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer113(10), 2734–2741 (2008).
   PubMed Web of Science ®Google Scholar
• Garbo LE, Flynn PJ, MacRae MA, Rauch MA, Wang Y, Kolibaba KS. Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. Invest. New Drugs27(5), 476–481 (2009).
   PubMed Web of Science ®Google Scholar
• Wang L, Fayad L, Hagemeister FB et al. A Phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts)114(22), 2719–2719 (2009).
   Google Scholar
• Batchelor T, Carson K, O’Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol.21(6), 1044–1049 (2003).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol.25(11), 1350–1356 (2007).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood101(2), 466–468 (2003).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Nolan C, Abrey LE. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J. Neuroonc.75(1), 71–83 (2005).
   PubMedGoogle Scholar
• Carrabba MG, Reni M, Foppoli M et al. Treatment approaches for primary CNS lymphomas. Expert Opin. Pharmacother.11(8), 1263–1276 (2010).
   PubMed Web of Science ®Google Scholar
• Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology63(5), 901–903 (2004).
   PubMed Web of Science ®Google Scholar
• Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer101(1), 139–145 (2004).
   PubMed Web of Science ®Google Scholar
• Reni M, Zaja F, Mason W et al. Temozolomide as salvage treatment in primary brain lymphomas. Br. J. Cancer96(6), 864–867 (2007).
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood113(16), 3673–3678 (2009).
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom’s macroglobulinemia. Clin. Lymphoma5(4), 273–277 (2005).
   PubMedGoogle Scholar
• Ghobrial IM, Hong F, Padmanabhan S et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J. Clin. Oncol.28(8), 1422–1428 (2010).
   PubMed Web of Science ®Google Scholar
• Treon SP, Steven P. Thalidomide and rituximab in Waldenstrom’s macroglobulinemia. Blood112(12), 4452–4457 (2008).
   PubMed Web of Science ®Google Scholar
• Lim MS, de Leval L, Quintanilla-Martinez L. Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms. J. Hematop.2(2), 65–73 (2009).
   PubMedGoogle Scholar
• Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood103(8), 2920–2924 (2004).
   PubMed Web of Science ®Google Scholar
• Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol.26(25), 4124–4130 (2008).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res.22(2), 185–191 (1998).
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans JC, Van Marwijk KM, Lugtenburg PJ, Wijermans PW, Van Putten WJL, van Imhoff GW. Alemtuzumab-CHOP for aggressive T cell lymphoma. A Phase II HOVON 69 trial. Blood (ASH Annual Meeting Abstracts)112(11), 1999–1999 (2008).
   Google Scholar
• Kim SJ, Kim K, Park Y et al. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest. New Drugs DOI: 10.1007/s10637-010-9523-2 (2010) (Epub ahead of print).
   Google Scholar
• Weidmann E, Hess G, Chow KU et al. A Phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk. Lymphoma51(3), 447–455 (2010).
   PubMed Web of Science ®Google Scholar
• Rupoli S, Goteri G, Picardi P et al. Alemtuzumab in combination with interferon-{alpha} or gemcitabine in aggressive and advanced cutaneous T-cell lymphomas: report of preliminary results. Blood (ASH Annual Meeting Abstracts)112(11), 5000–5000 (2008).
   Google Scholar
• Witzig TE, Wiernik PH, Moore T et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J. Clin. Oncol.27(32), 5404–5409 (2009).
   PubMed Web of Science ®Google Scholar
• Borghaei H, Smith M, Millenson M, Shafer D, Thibodeau L, Schilder R. Phase I trial of combination therapy with 90Y ibritumomab tiuxetan and gemcitabine in patients with non-Hodgkin’s lymphoma. Blood (ASH Annual Meeting Abstracts)108(11), 4710–4710 (2006).
   Google Scholar
• Evens AM, Spies S, Patton D et al. A Phase I/II trial of radioimmunotherapy (RIT) with 90Yttrium–Ibritumomab tiuxetan (Zevalin®; 90Y–Zevalin) combined with the redox-active agent motexafin gadolinium (MGd): prompt and high remission rates in patients with rituximab-refractory non-Hodgkin’s lymphoma (NHL). Blood (ASH Annual Meeting Abstracts)110(11), 2558 (2007).
   Google Scholar
• Gopal AK, Rajendran JG, Gooley TA et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults 60 years old with relapsed or refractory B-cell Lymphoma. J. Clin. Oncol.25(11), 1396–1402 (2007).
   PubMed Web of Science ®Google Scholar
• Winter JN, Inwards DJ, Spies S et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.27(10), 1653–1659 (2009).
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer115(13), 2824–2836 (2009).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Lerner S et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood92(4), 1165–1171 (1998).
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood107(3), 885–891 (2006).
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet370(9583), 230–239 (2007).
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukaemia: US intergroup trial E2997. J. Clin. Oncol.25(7), 793–798 (2007).
   PubMed Web of Science ®Google Scholar
• Lin TS, Donohue KA, Byrd JC et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukaemia: final analysis of CALGB 10101. J. Clin. Oncol.28(29), 4500–4506 (2010).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Rai KR et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukaemia: final report of Cancer and Leukemia Group B study 19901. Leuk. Lymphoma50(10), 1589–1596 (2009).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Vazquez ER, Spigel DR et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer112(6), 1288–1295 (2008).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Cortes J et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol.19(5), 1414–1420 (2001).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol.16(8), 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood99(10), 3554–3561 (2002).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukaemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol.27(24), 3994–4001 (2009).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood101(1), 6–14 (2003).
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood100(9), 3115–3120 (2002).
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Consalvo MAI et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer104(12), 2743–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol.23(18), 4079–4088 (2005).
   PubMed Web of Science ®Google Scholar
• Wierda W, O’Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol.23(18), 4070–4078 (2005).
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol.28(10), 1756–1765 (2010).
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet376(9747), 1164–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Durig J et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, Phase II trial. Blood (ASH Annual Meeting Abstracts)114(22), 207 (2009).
   Web of Science ®Google Scholar
• Elter T, James R, Stilgenbauer S, Ritgen M, Hallek M, Engert A. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab in patients with relapsed/refractory CLL: interim analysis of the CLL2L trial of the German CLL study group. Blood (ASH Annual Meeting Abstracts)112(11), 3170 (2008).
   Google Scholar
• Badoux XC, Keating M, O’Brien S et al. Chemoimmunotherapy with cyclophosphomide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts)114(22), 3431 (2009).
   PubMedGoogle Scholar
• Engert A, Gercheva L, Robak T et al. Improved progression-free survival (PFS) of alemtuzumab (campath®, mabcampath®) plus fludarabine (fludara®) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukaemia: preliminary results from a Phase III randomized trial. Blood (ASH Annual Meeting Abstracts)114(22), 537 (2009).
   Google Scholar
• Lepretre S, Aurran T, Mahe B et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R; FCR) versus fludarabine (F), cyclophosphamide (C) and mabcampath (Cam; FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter Phase III trial of the French cooperative group on CLL and WM (FCGCLL/MW) and the ‘roupe Ouest-Est d’Etudes Des Leucemies Aigues Et Autres Maladies Du sang’ (GOELAMS): CLL2007FMP (for fit medically patients). Blood (ASH Annual Meeting Abstracts)114(22), 538–538 (2009).
   Web of Science ®Google Scholar